Literature DB >> 34149904

Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes.

Amany Samir1, Reda Abdel Tawab2, Hend M Eltayebi1.   

Abstract

Long non-coding RNAs (lncRNAs) have attracted widespread attention as potential biological and pathological regulators. lncRNAs are involved in several biological processes in cancer. Triple negative breast cancer (TNBC) is characterized by strong heterogeneity and aggressiveness. At present, the implication of microRNAs (miRs) and lncRNAs in immunotherapy has been poorly studied. Nevertheless, the blockade of immune checkpoints, particularly that of the programmed cell-death protein-1/programmed cell-death ligand-1 (PD-L1) axis, is considered as a principle approach in breast cancer (BC) therapy. The present study aimed to investigate the interaction between immune-modulatory upstream signaling pathways of the PD-L1 transcript that could enhance personalized targeted therapy. MDA-MB-231 cells were transfected with miR-182-5p mimics followed by RNA extraction and cDNA synthesis using a reverse transcription kit, and the expression levels of the target genes were assessed by reverse transcription-quantitative PCR. Furthermore, the expression levels of target genes were measured in tissues derived from 41 patients with BC, including patients with luminal BC and TNBC, as well as their adjacent lymph nodes. The results revealed that the expression levels of miR-182-5p, PD-L1 and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) were upregulated in MDA-MB-231 cells and BC tissues. However, X-inactive specific transcript (XIST) expression was downregulated in cancer tissues and TNBC cells. Following co-transfection of cells with small interfering RNAs specific for each target gene and miR-182-5p antagomirs, the effect of miR-182-5p was abolished in the presence of lncRNAs. Therefore, the results of the present study indicated that although miR-182-5p exhibited an oncogenic effect, XIST exerted a dominant effect on the regulation of the PD-L1 signaling pathway via the inhibition of the oncogenic function of MALAT1.
Copyright © 2021, Spandidos Publications.

Entities:  

Keywords:  X-inactive specific transcript; immunotherapy; long non-coding RNAs; metastasis-associated lung adenocarcinoma transcript 1; programmed cell-death ligand-1; triple negative breast cancer

Year:  2021        PMID: 34149904      PMCID: PMC8200942          DOI: 10.3892/ol.2021.12854

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  73 in total

Review 1.  PD-1/PD-L1 Pathway in Breast Cancer.

Authors:  Florian Schütz; Stefan Stefanovic; Luisa Mayer; Alexandra von Au; Christoph Domschke; Christof Sohn
Journal:  Oncol Res Treat       Date:  2017-03-27       Impact factor: 2.825

2.  Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

Authors:  Steven C Kao; Yuen Yee Cheng; Marissa Williams; Michaela B Kirschner; Jason Madore; Trina Lum; Kadir H Sarun; Anthony Linton; Brian McCaughan; Sonja Klebe; Nico van Zandwijk; Richard A Scolyer; Michael J Boyer; Wendy A Cooper; Glen Reid
Journal:  J Thorac Oncol       Date:  2017-06-16       Impact factor: 15.609

3.  A Primary Role for the Tsix lncRNA in Maintaining Random X-Chromosome Inactivation.

Authors:  Srimonta Gayen; Emily Maclary; Emily Buttigieg; Michael Hinten; Sundeep Kalantry
Journal:  Cell Rep       Date:  2015-05-14       Impact factor: 9.423

Review 4.  The emergence of lncRNAs in cancer biology.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2011-10       Impact factor: 39.397

Review 5.  [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].

Authors:  Audrey Monneur; Anthony Gonçalves; François Bertucci
Journal:  Bull Cancer       Date:  2018-02-16       Impact factor: 1.276

6.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Authors:  Jaikumar Duraiswamy; Karen M Kaluza; Gordon J Freeman; George Coukos
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

7.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.

Authors:  Lorenzo F Sempere; Mette Christensen; Asli Silahtaroglu; Mads Bak; Catherine V Heath; Gary Schwartz; Wendy Wells; Sakari Kauppinen; Charles N Cole
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

8.  LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.

Authors:  Ming Zhang; Ning Wang; Peng Song; Yingqiang Fu; Yanlv Ren; Zhigao Li; Jinsong Wang
Journal:  Cell Prolif       Date:  2020-07-20       Impact factor: 6.831

9.  Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer.

Authors:  Zhang Xiping; Chen Bo; Yang Shifeng; Yu Feijiang; Yang Hongjian; Cheng Qihui; Tang Binbin
Journal:  Oncotarget       Date:  2017-12-18

10.  MiR-182-5p Knockdown Targeting PTEN Inhibits Cell Proliferation and Invasion of Breast Cancer Cells.

Authors:  Yue Sheng Zhao; Wei Chao Yang; Hong Wei Xin; Ji Xia Han; Su Gang Ma
Journal:  Yonsei Med J       Date:  2019-02       Impact factor: 2.759

View more
  1 in total

Review 1.  Functional interplay between long non-coding RNAs and Breast CSCs.

Authors:  Bashdar Mahmud Hussen; Ramiar Kamal Kheder; Sara Tharwat Abdullah; Hazha Jamal Hidayat; Heshu Sulaiman Rahman; Abbas Salihi; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Cancer Cell Int       Date:  2022-07-21       Impact factor: 6.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.